First in Human: PROCLAIM and upliFT-D Trials Bring Gene Therapy to Frontotemporal Dementia
July 27th 2023With up to 20% of incidences of FTD driven by genetic mutations, multiple gene therapy companies have initiated clinical trials of AAV-mediated treatments for a patient population with little to no options.